Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled RT001 study in ALS
NL-OMON51123Phase 2Active, not recruiting
- Sponsor
- Retrotope
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing RT001 with Placebo (2 arms). Primary endpoint: Change from baseline in revised ALS Functional Rating Scale. Started Feb 2021; status: active, not recruiting.
02
Drugs
RT001
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON51123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51123.